Haplo HCT vs Haplo-cord HCT for Patients With AML (NCT03719534) | Clinical Trial Compass
CompletedPhase 3
Haplo HCT vs Haplo-cord HCT for Patients With AML
China134 participantsStarted 2017-06-01
Plain-language summary
Patients who have acute myeloid leukemia and will undergo haplo-identical donor hematopoeitic cell transplantation (haplo HCT) are potential candidates of this trial. Participants will randomized into two arms: Arm A will undergo a typical haplo HCT, while Arm B will receive an coinfusion of an unrelated cord blood unit (haplo-cord HCT) in addition to Arm A. Progression-free survival, overall survival, cumulative incidence of relapse and nonrelapse mortality will be recorded as endpoints.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18 to 60 years old;
✓. Patients with AML;
✓. With available minimal residual disease (MRD) parameters assessed by flow cytometry (FCM) and/or quantitative real-time PCR (qPCR)
✓. Having no available HLA-matched donor, and willing to undergo haplo-HCT and having a suitable haploidentical donor
✓. With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
✓. Signing informed consent form, having the ability to comply with study and follow-up procedures